Metagenomi Therapeutics, Inc. (MGX): Total Liabilities
$62.51M
As of 2025-12-31
$61.13M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $62.51M | -30.3% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $89.74M | -40.0% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $149.67M | n/a | 2025-03-17, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $62.51M | -30.3% |
| Alector, Inc. (ALEC) | 2025-12-31 | $262.59M | -23.1% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $576.73M | +101.9% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $21.54M | +92.0% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $62.17M | -22.3% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $104.17M | -16.2% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $102.49M | -23.3% |
| Pelthos Therapeutics Inc. (PTHS) | 2025-12-31 | $91.52M | n/m |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $163.15M | +14.6% |
Compare MGX, ALEC, SCLX, LENZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗